ZA201202642B - Monoclonal antibodies to progastrin and their uses - Google Patents

Monoclonal antibodies to progastrin and their uses

Info

Publication number
ZA201202642B
ZA201202642B ZA2012/02642A ZA201202642A ZA201202642B ZA 201202642 B ZA201202642 B ZA 201202642B ZA 2012/02642 A ZA2012/02642 A ZA 2012/02642A ZA 201202642 A ZA201202642 A ZA 201202642A ZA 201202642 B ZA201202642 B ZA 201202642B
Authority
ZA
South Africa
Prior art keywords
progastrin
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
ZA2012/02642A
Other languages
English (en)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frederic Hollande
Original Assignee
Inst Nat De La Sante Et De La Rech Medicale ( Inserm)
Centre Nat De La Rech Scient (Cnrs)
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201202642(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat De La Sante Et De La Rech Medicale ( Inserm), Centre Nat De La Rech Scient (Cnrs), Servier Lab filed Critical Inst Nat De La Sante Et De La Rech Medicale ( Inserm)
Publication of ZA201202642B publication Critical patent/ZA201202642B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
ZA2012/02642A 2009-10-16 2012-04-12 Monoclonal antibodies to progastrin and their uses ZA201202642B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
ZA201202642B true ZA201202642B (en) 2013-06-26

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02642A ZA201202642B (en) 2009-10-16 2012-04-12 Monoclonal antibodies to progastrin and their uses

Country Status (42)

Country Link
US (7) US9611320B2 (cg-RX-API-DMAC10.html)
EP (2) EP3421493B1 (cg-RX-API-DMAC10.html)
JP (3) JP5985987B2 (cg-RX-API-DMAC10.html)
KR (2) KR20120091221A (cg-RX-API-DMAC10.html)
CN (2) CN102791735B (cg-RX-API-DMAC10.html)
AP (1) AP2012006262A0 (cg-RX-API-DMAC10.html)
AR (1) AR078659A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010306119A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012008818B1 (cg-RX-API-DMAC10.html)
CA (1) CA2777691C (cg-RX-API-DMAC10.html)
CL (1) CL2012000914A1 (cg-RX-API-DMAC10.html)
CR (1) CR20120184A (cg-RX-API-DMAC10.html)
CU (1) CU24196B1 (cg-RX-API-DMAC10.html)
CY (1) CY1120913T1 (cg-RX-API-DMAC10.html)
DK (1) DK2488551T3 (cg-RX-API-DMAC10.html)
EA (2) EA029271B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011796A (cg-RX-API-DMAC10.html)
ES (2) ES2973217T3 (cg-RX-API-DMAC10.html)
GE (1) GEP201706604B (cg-RX-API-DMAC10.html)
GT (1) GT201200114A (cg-RX-API-DMAC10.html)
HN (1) HN2012000708A (cg-RX-API-DMAC10.html)
HR (1) HRP20181645T1 (cg-RX-API-DMAC10.html)
IL (2) IL219019B (cg-RX-API-DMAC10.html)
IN (1) IN2012DN03348A (cg-RX-API-DMAC10.html)
LT (1) LT2488551T (cg-RX-API-DMAC10.html)
MA (1) MA33747B1 (cg-RX-API-DMAC10.html)
MX (1) MX351635B (cg-RX-API-DMAC10.html)
NI (1) NI201200054A (cg-RX-API-DMAC10.html)
NZ (2) NZ701709A (cg-RX-API-DMAC10.html)
PE (1) PE20121649A1 (cg-RX-API-DMAC10.html)
PH (1) PH12012500711B1 (cg-RX-API-DMAC10.html)
PL (2) PL3421493T3 (cg-RX-API-DMAC10.html)
PT (1) PT2488551T (cg-RX-API-DMAC10.html)
RS (1) RS57966B1 (cg-RX-API-DMAC10.html)
SG (1) SG10201704933PA (cg-RX-API-DMAC10.html)
SI (1) SI2488551T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800628T1 (cg-RX-API-DMAC10.html)
TN (1) TN2012000159A1 (cg-RX-API-DMAC10.html)
TW (1) TWI537002B (cg-RX-API-DMAC10.html)
UA (1) UA106771C2 (cg-RX-API-DMAC10.html)
WO (1) WO2011045080A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201202642B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
MX378944B (es) 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN108780091A (zh) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
KR102620651B1 (ko) * 2015-12-31 2024-01-04 신케레스 에스.에이 알.엘. 암 발생의 위험도를 평가하기 위한 조성물 및 방법
ES3011729T3 (en) 2015-12-31 2025-04-08 Ecs Progastrin Sa Compositions and methods for detecting and treating gastric cancer
SG11201908998XA (en) * 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CN110678753B (zh) * 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 用于治疗肺癌的组合物和方法
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949B (zh) * 2022-12-12 2026-05-15 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
EP4509528A1 (en) * 2023-08-16 2025-02-19 Barrelman Biosciences LLC Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN118126177A (zh) * 2023-11-22 2024-06-04 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
PL2040753T3 (pl) * 2006-05-22 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitory progastryny w leczeniu raka okrężnicy
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
DK2488551T3 (en) 2018-10-08
CL2012000914A1 (es) 2012-09-14
LT2488551T (lt) 2018-10-25
EA201200597A1 (ru) 2012-12-28
EP2488551A2 (en) 2012-08-22
GT201200114A (es) 2014-08-11
PL2488551T3 (pl) 2019-01-31
US11299542B2 (en) 2022-04-12
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
MX2012004400A (es) 2012-06-27
US20220195035A1 (en) 2022-06-23
MX351635B (es) 2017-10-23
EP2488551B1 (en) 2018-07-25
SMT201800628T1 (it) 2019-01-11
JP2017212992A (ja) 2017-12-07
ES2973217T3 (es) 2024-06-19
JP5985987B2 (ja) 2016-09-06
JP2015145380A (ja) 2015-08-13
ECSP12011796A (es) 2012-06-29
EA029271B1 (ru) 2018-03-30
CR20120184A (es) 2012-08-20
MA33747B1 (fr) 2012-11-01
CU20120060A7 (es) 2013-04-19
US20110117086A1 (en) 2011-05-19
NZ701709A (en) 2016-06-24
HN2012000708A (es) 2015-06-22
UA106771C2 (uk) 2014-10-10
CU24196B1 (es) 2016-09-30
CN104628857A (zh) 2015-05-20
JP2013507138A (ja) 2013-03-04
TWI537002B (zh) 2016-06-11
TN2012000159A1 (en) 2013-12-12
EP3421493B1 (en) 2024-01-17
US20180022802A1 (en) 2018-01-25
TW201119675A (en) 2011-06-16
US20170174761A1 (en) 2017-06-22
US20170306011A1 (en) 2017-10-26
JP6272793B2 (ja) 2018-01-31
IN2012DN03348A (cg-RX-API-DMAC10.html) 2015-10-23
EP3421493A1 (en) 2019-01-02
CN102791735A (zh) 2012-11-21
NI201200054A (es) 2012-08-20
KR101640520B1 (ko) 2016-07-19
ES2690943T3 (es) 2018-11-23
PL3421493T3 (pl) 2024-04-29
KR20120091221A (ko) 2012-08-17
IL219019A0 (en) 2012-06-28
NZ599971A (en) 2014-12-24
SI2488551T1 (sl) 2019-01-31
WO2011045080A2 (en) 2011-04-21
US9611320B2 (en) 2017-04-04
AP2012006262A0 (en) 2012-06-30
US10385125B2 (en) 2019-08-20
RS57966B1 (sr) 2019-01-31
SG10201704933PA (en) 2017-07-28
EA201791876A1 (ru) 2018-01-31
PH12012500711B1 (en) 2019-04-24
PE20121649A1 (es) 2012-12-08
IL219019B (en) 2019-05-30
HK1178183A1 (zh) 2013-09-06
CA2777691C (en) 2018-02-27
PT2488551T (pt) 2018-10-31
BR112012008818B1 (pt) 2021-10-19
CA2777691A1 (en) 2011-04-21
US10385124B2 (en) 2019-08-20
IL254004A0 (en) 2017-10-31
GEP201706604B (en) 2017-01-25
US20170306012A1 (en) 2017-10-26
KR20150082672A (ko) 2015-07-15
CY1120913T1 (el) 2019-12-11
WO2011045080A3 (en) 2011-07-07
IL254004B2 (en) 2023-06-01
EP3421493C0 (en) 2024-01-17
US10377821B2 (en) 2019-08-13
US10385126B2 (en) 2019-08-20
US20200002413A1 (en) 2020-01-02
AU2010306119A1 (en) 2012-05-03
BR112012008818A2 (en) 2018-05-22
HRP20181645T1 (hr) 2018-12-14
PH12012500711A1 (en) 2012-11-12

Similar Documents

Publication Publication Date Title
SG10201704933PA (en) Monoclonal antibodies to progastrin and their uses
ZA201107511B (en) Antibodies specific to cadherin-17
ZA201200732B (en) Fully human antibodies to btla
IL218724A0 (en) Endoglin antibodies
EP2542262A4 (en) Monoclonal antibodies directed to cd20
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201107486B (en) Anti-tnf-x antibodies and their uses
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
IL217919A0 (en) Humanized anti-cdcp1 antibodies
ZA201202227B (en) Monoclonal antibodies
ZA201105918B (en) Fully human antibodies specific to cadm1
IL217225A0 (en) Humanised antibodies to toll - like receptor 2 and uses thereof
EP2427496A4 (en) ANTIBODIES AGAINST VEGF-D
GB0920324D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0908945D0 (en) Antibodies
GB0911712D0 (en) Antibody